Keywords: Zealand Pharma, Sanofi, Lixisenatide, Lyxumia, Type 2 diabets, Milestone

$20 million lixisenatide milestone for Zealand Pharma

Article | 13 February 2012

Print This

Danish peptide drug discovery firm Zealand Pharma (Nasdaq OMX Copenhagen: ZEAL) says it will receive a milestone payment of $20 million ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in